VIA Pharmaceuticals (VIAP) Inactive 10-Q2004 Q2 Quarterly report

Filed: 16 Aug 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: academic, advisor, anniversary, appointment, Arizona, Baptist, BayStar, Bonanza, Chairman, Committee, constituting, currency, Daniel, denominated, detailed, Director, DKR, Duke, East, ensuing, Episcopal, Eric, Ernst, escrow, Europe, expanding, Falkenberg, fewer, Fiduciary, firm, Florida, Fuqua, gave, Gilstrap, Heart, Highline, Hospital, implementation, independent, Institute, Institutional, interviewing, Ivor, John, journalism, Larson, length, LLP, LP, Luke, Master, Mayo, Medstar, Merriman, Nichol, Omicron, opportunity, peripheral, person, Pharand, physician, Piedmont, plasmid, President, proxy, publicly, QP, quorum, ratified, recruitment, Regional, repaid, resignation, Riverside, Rochester, Ronald, Royston, Rush, salary, Schatz, Schmitt, Scottsdale, Secretary, serve, Smithfield, SoundShore, Southwest, staffing, subscription, Swedish, Tennessee, thirteen, Tritt, unconverted, University, unregistered, upcoming, utilizing, Vice, Victor, Washington, Young

Removed: alleged, amendment, application, asserting, biological, California, catheter, controlled, conversion, County, Court, declared, developed, Diego, dose, employed, Genome, Human, incur, initiate, injection, lawsuit, license, licensed, longer, lower, official, part, Paul, PMSI, previously, randomized, ranging, Raschke, refused, San, Science, sell, September, state, study, subsequent, suffered, Superior, support, United, William, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VIAP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Corautus Genetics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard E. Otto, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 16, 2004

/s/ RICHARD E. OTTO

Name: Richard E. Otto

Title: President and Chief Executive Officer

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Corautus Genetics Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert T. Atwood, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 16, 2004

/s/ ROBERT T. ATWOOD

Name: Robert T. Atwood

Title: Executive Vice President and Chief
Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.